Tue, May 21, 2013, 10:50 AM EDT - U.S. Markets close in 5 hrs 10 mins
and then let's see....
How do you value ELN now? It has to be more than the cash as they have a lot of R&D, irrespective of pipeline drugs. An acquirer has other routes to access to cash if needed, for example.
It may be the beginning of a bidding war between ELN management and Royalty Pharma or another. The math may establish the valuation, but it may not.
We'll see.
11 is too low.